Program Coordinator: Laura Kasman, Ph.D. [email protected].
-
date post
19-Dec-2015 -
Category
Documents
-
view
229 -
download
3
Transcript of Program Coordinator: Laura Kasman, Ph.D. [email protected].
Program Coordinator:Laura Kasman, [email protected]
M&I program currentlyM&I program currently 17 Ph.D. students 4 MD/Ph.D. students 1 DMD/Ph.D. student 2 Masters students 15 Departmental faculty 40 Total Program faculty
Program RequirementsProgram Requirements 6 credits in advanced M&I courses in 2nd
year
Written qualifying exam, summer after 2nd year
Thesis proposal defense, usually sometime in 3rd year for admission to candidacy
12 advanced credits total, not including M&I Seminar
M&I Advanced course offeringsM&I Advanced course offeringsOffered Every Year
FALL SPRING
MBIM 613G Infection MBIM 623G Dental MicrobiologyMBIM 614G Immunity MBIM 702 Oral Immunobiology
MBIM 905 Translational Genomics M&I Selective
MBIM 770 Seminar MBIM 770 Seminar
Offered academic cycles beginning in odd years: 2007, 2009, 2011...
MBIM 742 Advanced Microbiology MBIM731 Advanced Topics in Immunology
Offered academic cycles beginning in even years: 2008, 2010, 2012...
MBIM 725 Virology MBIM 772 Environmental Micro
MBIM 775 Special Topics MBIM 775A Bioentrepreneurship
MBIM 779 Immunogenetics
Departmental vs. Program FacultyDepartmental vs. Program Faculty
Department Faculty have M&I as their home department
M&I Program Faculty can be faculty members from any MUSC department that have research interests related to microbiology or immunology
Faculty can be affiliated with more than one graduate program
M&I Department Faculty InterestsM&I Department Faculty Interests
bacteriology
virology
immunology
gene therapy
BacteriologistsBacteriologists
Michael Schmidt Hal May Ed Balish
VirologistsVirologists
Natalie Sutkowski John Y. Dong Laura Kasman
ImmunologistsImmunologists
Janardan Stephen Gabriel Aziz Carl Pandey Tomlinson Virella Haque Atkinson
Also Natalie Sutkowski
Tumor Immunologists & Gene TherapyTumor Immunologists & Gene Therapy
James Norris Christina Xiang Liu Semyon Voelkel-Johnson Rubinchik
Also Stephen Tomlinson & John Dong
Program FacultyProgram FacultySurgerySurgery Prabhakar Baliga Mike Nishimura Kenneth Chavin David Cole Yi Zhang
PathologyPathology Amanda LaRue
OtolaryngologyOtolaryngology Rita Young
Neurosciences/NeurologyNeurosciences/Neurology Narendra Banik Narayan Bhat James Cook William Tyor Swapan Ray
PediatricsPediatrics Inderjit Singh Isabel Virella-Lowell
Program FacultyProgram FacultyCollege of Dental MedicineCollege of Dental Medicine Robert Boackle Caroline Westwater
Radiation OncologyRadiation Oncology Sebastiano Gattoni-Celli
College of Pharmaceutical College of Pharmaceutical SciencesSciences
Craig Beeson
Cell Biology & AnatomyCell Biology & Anatomy Titus Reaves
RheumatologyRheumatology James Oates Maria Trojanowska Gary Gilkeson
BiochemistryBiochemistry Greg Warr Maurizio Del Poeta
Division of Infectious Division of Infectious DiseaseDisease
Christopher Parsons
Entrepreneurship by M&I facultyEntrepreneurship by M&I faculty
Company Faculty Technology
GenPharGenPhar Dr. Dong Adenovirus-based subunit vaccines
SphingoGeneSphingoGene Dr. Norris Ceramide-modifying
anti-cancer agents
TaligenTaligen Dr.
Tomlinson
Therapeutic complement inhibitors
MFC TechMFC Tech Dr. May Bacterial electricity generation, Microbial fuel
cells
MOUNT PLEASANT, SC (AUGUST 30, 2007) - Groundbreaking ceremony for new facility at Innovation Park, in the economic development zone of The Market at Oakland.
MOUNT PLEASANT, SC (AUGUST 30, 2007) - Groundbreaking ceremony for new facility at Innovation Park, in the economic development zone of The Market at Oakland.
GenPhar, Inc. is a biopharmaceutical company dedicated to providing vaccines that protect against infectious diseases with great socio-economic impacts worldwide.
Biodefense programs: GenPhar's vaccine platform is ideally designed for biodefense because one vaccine can prevent infection from multiple virus subtypes.
James S. Norris, PhDCo-Founder, SphingoGene, Inc.
http://www.sphingogene.comProfessor and Chairman, MUSC
SphingoGene, Inc.
NH CO
O H 12
O H
(2S, 3R, 4E) D-erythro -Ceramide
34
5
n
SphingoGene, Inc. is focused on commercialization of small molecule therapeutics that modify ceramide metabolism to overcome resistance to chemo and radiation therapy and promote apoptosis in cancer cells. Ceramide is a “tumor suppressor sphingolipid” involved in regulation of cell death. SphingoGene, Inc.’s molecules are rationally designed and proven to inhibit enzymes that create resistance to conventional cancer therapies. Our goal is to utilize these small molecules in combination with “standard of care” radiation or chemotherapy to enhance cancer cell death.
Commercial Lipidomic Services
Molecular diagnostic to predict patientResponse
Combination therapy for standard of care
Therapies in cancer patients (chemo, radiation and gene therapy
Products and Services
Controlling Inflammation to Treat Human DiseaseApplying novel technologies to create better treatmentsContact: Woodruff Emlen [email protected]
Taligen Therapeutics, Inc. is a development stage biotechnology company with novel technology to modulate and regulate activation of the complement system. Inappropriate complement activation leading to inflammation is a major contributor to a large number of human diseases.
Taligen has proof of concept data in animal models of diseases as diverse as asthma, macular degeneration, immune renal disease, inflammatory arthritis, ischemia-reperfusion injury, stroke and traumatic brain injury.
Product DevelopmentCurrently focused on the areas of asthma and age related macular degeneration.
Stephen Tomlinson, [email protected]
Dr. Hal May, Ph.D.VP, MFC Technologies LLC
http://[email protected] Assoc. Prof. [email protected]
Microbially Generated Electricity
Increase Biofuel Production
24/7 Remote Power, Sensor Control
Control Waste, Odor and Algae
MFC Tech is focused on the development of microbial fuel cell technology (MFCs), which utilizes the ability of bacteria to generate electricity.
Patentable approaches are targeted for the enhancement of waste management and electricity generation, namely…
24/7 remote power generation such as along highways and in retention ponds
Development of specific sensors or the powering of sensors in remote locations
Enhancement of biofuel production through the application of MFC technology to cellulosic ethanol fermentation
The reduction of agricultural waste, odors and algal blooms in waste lagoons and retention ponds